Paul Logan: Decoding the Words ‘He’s on blood thinners’
Paul Logan, Founder of Advanced Practice Ready, shared a post on LinkedIn:
“‘He’s on blood thinners.’
What does that even mean?
- Anticoagulants?
- Antiplatelet agents?
- Both?
It’s imprecise.
And imprecise language in clinical settings leads to imprecise thinking. And sometimes ‘precisely’ the wrong outcome.
An anticoagulant (warfarin, apixaban, rivaroxaban, heparin) inhibits clotting factors in the coagulation cascade.
It prevents thrombus formation and propagation.
We use them for atrial fibrillation, DVT, PE, and mechanical valves, among others.
An antiplatelet agent (aspirin, clopidogrel, ticagrelor, prasugrel) inhibits platelet aggregation.
Different mechanism entirely.
We use them after PCI, in ACS, and for secondary prevention of atherosclerotic events.
And we keep going back and forth on their value for primary prevention.
- They are not interchangeable.
- They don’t do the same thing.
- They don’t protect against the same problems.
So let’s stop referring to them like they are the same.
A patient with a brand new drug-eluting stent who’s on apixaban for afib is not ‘covered’ for stent thrombosis.
The anticoagulant doesn’t replace the antiplatelet.
A patient on DAPT after a PCI is not ‘covered’ for their afib.
The antiplatelets don’t prevent cardioembolic stroke the way an anticoagulant does.
When you say ‘blood thinner,’ you’ve collapsed two entirely different pharmacologic strategies into one word.
And the patient hears it that way too. They think one pill handles everything.
Call the drug what it is.
Call the mechanism what it is. Your patient’s safety starts with your precision.
The APP Cardiology Academy launches May 1 with a full module on antithrombotic therapy for NPs and PAs.”
Stay updated with Hemostasis Today.
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial
-
Sep 14, 2026, 23:23Farjah Algahtani: Stroke Incidence and Risk Factors in Saudi Patients with Sickle Cell Disease
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation
-
Sep 14, 2026, 20:48Valerie Dehondt: Nutritional Anemia Is Associated With Increased Risk of Severe COPD Exacerbations
-
Sep 14, 2026, 20:46Nupur Choudhury: Exploring AI-Based Detection of Anemia Using Eye and Fingernail Images